Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Mitochondrial medicine reaches inflection point as new delivery methods and first drug approvals converge

Mitochondrial medicine reaches inflection point as new delivery methods and first drug approvals converge

New Capabilities
By Newzino Staff |

After decades without treatments, mitochondrial diseases now face an expanding arsenal — from gene editing to organelle transplantation

Today: Red blood cell capsule technique delivers mitochondria with 80% efficiency

Overview

For most of modern medicine's history, diseases caused by defective mitochondria — the structures inside cells that generate energy — have been essentially untreatable. Doctors could manage symptoms, but the broken power plants themselves were beyond reach. Now, within a six-month span, the United States Food and Drug Administration (FDA) has approved the first two drugs targeting mitochondrial diseases, and a Chinese research team has demonstrated a method to physically transplant healthy mitochondria into diseased cells with sixteen times the efficiency of previous approaches.

In This Story

3 Videos
3 People
XL
James McCully John Zhang
3 Orgs
Guangzhou Institutes of Biomedicine and Health (GIBH) Stealth BioTherapeutics
MT
10 Events
4 Key Stats
~80%
4 Scenarios
Capsule technique reaches human trials within three years
2 Context
Gene therapy's crash and revival (1990-2023)

Key Indicators

~80%
Cell uptake with new capsule method
Previous methods achieved less than 5% uptake — a roughly 16-fold improvement
1 in 4,300
People affected by mitochondrial diseases
One of the most common groups of inherited metabolic disorders, often misdiagnosed
2
FDA-approved mitochondrial therapies
Both approved in late 2025, after decades with zero approved treatments
~20%
Survival extension in Leigh syndrome mice
Capsule-treated mice survived roughly two weeks longer than those given uncoated mitochondria

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

XL
Xingguo Liu
Active researcher at GIBH
 James McCully
James McCully
Active researcher at Boston Children's Hospital
 John Zhang
John Zhang
Founder of New Hope Fertility Center, New York

Organizations Involved

Guangzhou Institutes of Biomedicine and Health (GIBH)
Guangzhou Institutes of Biomedicine and Health (GIBH)
Government Research Institute
Developed the mitochondrial capsule technique

A research institute under the Chinese Academy of Sciences, established in partnership with the city of Guangzhou and Guangdong Province, focused on biomedical and health sciences.
Stealth BioTherapeutics
Stealth BioTherapeutics
Biopharmaceutical Company
Maker of first FDA-approved mitochondrial therapy

The company behind elamipretide (FORZINITY), the first FDA-approved drug that directly targets mitochondrial function, approved for Barth syndrome in September 2025.
MT
Minovia Therapeutics
Biopharmaceutical Company
Clinical-stage mitochondrial transplantation company

An Israeli biotech developing Mitochondrial Augmentation Therapy, which loads healthy mitochondria into a patient's own blood-forming stem cells for reinfusion.

Timeline

  1. Red blood cell capsule technique delivers mitochondria with 80% efficiency

    Research

    A team at the Guangzhou Institutes of Biomedicine and Health publishes results in Cell showing that wrapping healthy mitochondria in red blood cell membranes allows them to bypass cellular defenses. The technique achieved roughly 80% cell uptake — up from less than 5% — and extended survival in Leigh syndrome mice by about 20%.

  2. Second mitochondrial drug approved by FDA

    Regulatory

    The FDA approves KYGEVVI (doxecitine and doxribtimine) by UCB for thymidine kinase 2 deficiency, which reduced overall risk of death by approximately 86% compared to untreated patients.

  3. First mitochondrial drug wins FDA approval

    Regulatory

    The FDA grants accelerated approval to elamipretide (FORZINITY) by Stealth BioTherapeutics for Barth syndrome — the first drug specifically targeting mitochondrial function ever approved in the United States.

  4. Eight healthy three-parent babies reported in UK

    Clinical

    Newcastle University publishes results confirming eight healthy babies born via mitochondrial donation, with disease-causing mutations either undetectable or at very low levels.

  5. Minovia reports first clinical efficacy in children

    Clinical

    Israeli biotech Minovia Therapeutics reports the first clinical data showing disease-modifying effects from mitochondrial augmentation therapy in children with Pearson syndrome.

  6. First three-parent baby born

    Clinical

    A boy conceived via spindle transfer is born in Mexico to a Jordanian couple. The mother carried Leigh syndrome mutations and had lost two children to the disease. The procedure was led by John Zhang of New Hope Fertility Center.

  7. UK legalizes mitochondrial replacement therapy

    Regulatory

    The United Kingdom becomes the first country to explicitly legalize mitochondrial donation in embryos, approving both maternal spindle transfer and pronuclear transfer techniques.

  8. First mitochondrial transplant in a human patient

    Clinical

    At Boston Children's Hospital, James McCully and Sitaram Emani transplant a patient's own mitochondria into damaged heart tissue during surgery. Eighty percent of treated children came off life support, double the historical rate.

  9. First mitochondrial disease diagnosed in a living patient

    Discovery

    Swedish endocrinologist Rolf Luft identifies a woman with the highest metabolic rate ever recorded in a human, caused by uncoupled mitochondria in her muscles. Only two cases of this condition have ever been confirmed.

  10. Leigh syndrome first described

    Discovery

    British neuropsychiatrist Denis Leigh describes a fatal childhood brain disease at Maudsley Hospital in London — later identified as a mitochondrial disorder.

Scenarios

1

Capsule technique reaches human trials within three years

Discussed by: Nature news coverage; mitochondrial disease patient advocacy groups

If the red blood cell membrane method replicates well in larger animal models and can be manufactured at scale, it could enter early human trials for Leigh syndrome or other severe mitochondrial diseases by 2028-2029. The technique's simplicity — using a commercially available mitochondria isolation kit and ordinary red blood cells — lowers the manufacturing barrier significantly compared to gene therapies. However, the 20% survival extension in mice, while meaningful, suggests the approach may need optimization or combination with other therapies before it transforms patient outcomes.

2

Gene editing of mitochondrial DNA overtakes transplantation approaches

Discussed by: Nature Biotechnology; researchers developing DdCBE and TALED base editors

Mitochondrial base editing tools can now correct point mutations in mitochondrial DNA with up to 82% efficiency in mice and 100% in offspring. If these tools prove safe and deliverable to affected tissues, they could offer permanent cures rather than the repeated treatments that transplantation requires. This path faces its own hurdles — off-target editing elsewhere in the mitochondrial genome and delivery to the central nervous system — but several research groups are advancing rapidly.

3

Mitochondrial therapies become standard of care for neurodegenerative diseases

Discussed by: Parkinson's disease researchers; mitochondrial therapy companies including Cellvie and Minovia

Mitochondrial dysfunction plays a role in Parkinson's, Alzheimer's, and other neurodegenerative conditions far more common than rare genetic mitochondrial diseases. If the capsule technique's Parkinson's results — near-normal motor function recovery in mice — translate to primates, it could open a market orders of magnitude larger than rare diseases. Several companies are already positioning for this broader application, though the gap between mouse models and human neurodegenerative disease is historically wide.

4

Clinical translation stalls due to manufacturing or safety hurdles

Discussed by: FDA regulatory experts; clinical mitochondrial transplantation researchers at Boston Children's Hospital

Isolated mitochondria maintain activity for only one to two hours on ice, and their outer membranes degrade at storage temperatures. Scaling production, ensuring quality control, and managing potential immune responses could delay or prevent clinical translation — a pattern seen repeatedly in cell therapy. The Boston Children's cardiac transplant work has been in clinical use for over a decade but remains limited to a single center, illustrating how difficult it is to standardize organelle-based therapies.

Historical Context

Gene therapy's crash and revival (1990-2023)

1990-2023

What Happened

In 1990, four-year-old Ashanthi de Silva became the first gene therapy success, treated for a severe immune deficiency. Nine years later, 18-year-old Jesse Gelsinger died in a University of Pennsylvania gene therapy trial after a massive immune reaction to the viral delivery vehicle — the first publicly identified death in gene therapy. The FDA temporarily halted all U.S. gene therapy trials.

Outcome

Short Term

Gene therapy research nearly stopped. Public trust collapsed and funding dried up for years.

Long Term

Researchers spent two decades developing safer delivery vehicles. By 2023, the FDA had approved gene-editing therapies for sickle cell disease, and dozens of gene therapies were in clinical use — but only after the field solved its delivery problem.

Why It's Relevant Today

Mitochondrial transplantation faces a parallel delivery challenge: getting therapeutic cargo into cells safely and efficiently. The capsule technique addresses exactly this bottleneck — much as safer viral vectors eventually unlocked gene therapy's potential.

First successful organ transplant (1954)

December 1954

What Happened

Dr. Joseph Murray performed the world's first successful kidney transplant at Peter Bent Brigham Hospital in Boston, between identical twins Richard and Ronald Herrick. The operation succeeded precisely because identical twins share the same immune profile, bypassing the rejection problem that had defeated all prior attempts.

Outcome

Short Term

Richard Herrick lived eight more years, married, and had children. The success proved organ transplantation was biologically possible.

Long Term

Murray won the 1990 Nobel Prize. It took another decade to develop immunosuppressive drugs that made transplants between non-identical individuals viable — transforming a twin-only curiosity into standard medicine.

Why It's Relevant Today

The mitochondrial capsule technique solves an analogous rejection problem at the cellular level. Just as the immune system attacks foreign organs, cells destroy foreign mitochondria. The red blood cell membrane disguise is, in essence, an immunosuppression strategy for organelles.

Sources

(7)
+1
Nature People's Daily Xinhua United Mitochondrial Disease Foundation Boston Children's Hospital Newcastle University Science